Pegaptanib Sodium for Macular Edema Secondary to Branch Retinal Vein Occlusion

American Journal of Ophthalmology

Volumn 149, Issue 1, 2010, Pages 147-154

  Wroblewski, John J ^a   Wells III, John A ^b   Gonzales, Christine R ^c  

^a Cumberland Valley Retina Consultants   (United States)

^b Palmetto Retina Center   (United States)

^c Retina and Vitreous Center of Southern Oregon   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

PEGAPTANIB;

ADULT; AGED; ARTICLE; BRANCH RETINAL VEIN OCCLUSION; CLINICAL ARTICLE; CLINICAL PRACTICE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIABETIC RETINOPATHY; DISEASE DURATION; DRUG EFFICACY; DRUG SAFETY; ENDOPHTHALMITIS; FEMALE; FOLLOW UP; HUMAN; MALE; MULTICENTER STUDY; OPTICAL COHERENCE TOMOGRAPHY; PRIORITY JOURNAL; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL; RETINA DETACHMENT; RETINA FOVEA; RETINA MACULA EDEMA; RETINA MACULA LUTEA; THICKNESS; TRAUMATIC CATARACT; UNITED STATES; VISUAL ACUITY;

AGED; AGED, 80 AND OVER; APTAMERS, NUCLEOTIDE; FEMALE; HUMANS; INJECTIONS; MACULAR EDEMA; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; RETINA; RETINAL VEIN OCCLUSION; TOMOGRAPHY, OPTICAL COHERENCE; TREATMENT OUTCOME; VASCULAR ENDOTHELIAL GROWTH FACTOR A; VISUAL ACUITY; VITREOUS BODY;

EID: 72049090107     PISSN: 00029394     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ajo.2009.08.005     Document Type: Article

References (57)

1. Jefferies P., Clemett R., and Day T. An anatomical study of retinal arteriovenous crossings and their role in the pathogenesis of retinal branch vein occlusions. Aust N Z J Ophthalmol 21 (1993) 213-217
2. Frangieh G.T., Green W.R., Barraquer-Somers E., and Finkelstein D. Histopathologic study of branch retinal vein occlusion. Arch Ophthalmol 100 (1982) 1132-1140
3. Trope G.E., Lowe G.D., McArdle B.M., et al. Abnormal blood viscosity and haemostasis in long-standing retinal vein occlusion. Br J Ophthalmol 67 (1983) 137-142
4. McGrath M.A., Wechsler F., Hunyor A.B., and Penny R. Systemic factors contributory to retinal vein occlusion. Arch Intern Med 138 (1978) 216-220
5. Janssen M.C.H., de Heijer M., Cruysberg J.R.M., Wollersheim H., and Bredie S.J.H. Retinal vein occlusion: A form of venous thrombosis or a complication of atherosclerosis?. Thromb Haemost 93 (2005) 1021-1026
6. Rehak J., and Rehak M. Branch retinal vein occlusion: pathogenesis, visual prognosis, and treatment modalities. Curr Eye Res 33 (2008) 111-131
7. Margolis R., Singh R.P., and Kaiser P.K. Branch retinal vein occlusion: clinical findings, natural history, and management. Compr Ophthalmol Update 7 (2006) 265-276
8. McIntosh R.L., Mohamed Q., Saw S.M., and Wong T.Y. Interventions for branch retinal vein occlusion: an evidence-based systematic review. Ophthalmology 114 (2007) 835-854
9. Branch Vein Occlusion Study Group. Argon laser scatter photocoagulation for prevention of neovascularization and hemorrhage in branch vein occlusion. Arch Ophthalmol 104 (1986) 34-41
10. Gutman F.A., and Zegarra H. The natural course of temporal retinal branch vein occlusion. Trans Am Acad Ophthalmol Otolaryngol 78 (1974) OP178-OP192
11. Hayreh S.S., Rojas P., Podhajsky P., Montague P., and Woolson R.F. Ocular neovascularization with retinal occlusion: III. Incidence of neovascularization with retinal vascular occlusion. Ophthalmology 90 (1983) 488-506
12. Gutman F.A. Macular edema in branch retinal vein occlusion: prognosis and management. Trans Sect Ophthalmol Am Acad Ophthalmol Otolaryngol 83 (1977) 488-495
13. Houtsmuller A.J., Vermeulen J.A., Klompe M., et al. The influence of ticlopidine on the natural course of retinal vein occlusion. Agents Actions Suppl 15 (1984) 219-229
14. Glacet-Bernard A., Coscas G., Chabanel A., Zourdani A., Lelong F., and Samama M.M. A randomized, double-masked study on the treatment of retinal vein occlusion with troxerutin. Am J Ophthalmol 118 (1994) 421-429
15. Poupard P., Eledjam J.J., Dupeyron G., et al. Role of acute normovolemic hemodilution in treating retinal venous occlusions. Ann Fr Anesth Reanim 5 (1986) 229-233
16. Hansen L.L., Wiek J., and Arntz R. Randomized study of the effect of isovolemic hemodilution in retinal branch vein occlusion. Fortschr Ophthalmol 85 (1988) 514-516
17. Branch Vein Occlusion Study Group. Argon laser photocoagulation for macular edema in branch vein occlusion. Am J Ophthalmol 98 (1984) 271-282
18. Cekic O., Chang S., Tseng J.J., et al. Intravitreal triamcinolone injection for treatment of macular edema secondary to branch retinal vein occlusion. Retina 25 (2005) 851-855
19. Chen S.D.M., Sundaram V., Lockhead J., and Patel C.K. Intravitreal triamcinolone for the treatment of ischemic macular edema associated with branch retinal vein occlusion. Am J Ophthalmol 141 (2006) 876-883
20. Patel P.J., Zaheer I., and Karia N. Intravitreal triamcinolone acetonide for macular oedema owing to retinal vein occlusion. Eye 22 (2008) 60-64
21. Cakir M., Dogan M., Bayraktar S., et al. Efficacy of intravitreal triamcinolone for the treatment of macular edema secondary to branch retinal vein occlusion in eyes with or without grid laser photocoagulation. Retina 28 (2008) 465-472
22. Osterloh M.D., and Charles S. Surgical decompression of branch retinal vein occlusions. Arch Ophthalmol 106 (1988) 1469-1471
23. Yamamoto S., Saito W., Yagi F., Takeuchi S., Sato E., and Mizunoya S. Vitrectomy with or without arteriovenous adventitial sheathotomy for macular edema associated with branch retinal vein occlusion. Am J Ophthalmol 138 (2004) 907-914
24. Starita C., Patel M., Katz B., and Adamis A.P. Vascular endothelial growth factor and the potential therapeutic use of pegaptanib (Macugen) in diabetic retinopathy. Dev Ophthalmol 39 (2007) 122-148
25. Senger D.R., Connolly D.T., Van de Water L., Feder J., and Dvorak H.F. Purification and NH2-terminal amino acid sequence of guinea pig tumor-secreted vascular permeability factor. Cancer Res 50 (1990) 1774-1778
26. Ferrara N. Vascular endothelial growth factor: basic science and clinical progress. Endocr Rev 25 (2004) 581-611
27. Noma H., Minamoto A., Funatsu H., et al. Intravitreal levels of vascular endothelial growth factor and interleukin-6 are correlated with macular edema in branch retinal vein occlusion. Graefes Arch Clin Exp Ophthalmol 244 (2006) 309-315
28. Noma H., Funatsu H., Yamasaki M., et al. Aqueous humour levels of cytokines are correlated to vitreous levels and severity of macular oedema in branch retinal vein occlusion. Eye 22 (2008) 42-48
29. Boyd S.R., Zachary I., Chakravarthy U., et al. Correlation of increased vascular endothelial growth factor with neovascularization and permeability in ischemic central vein occlusion. Arch Ophthalmol 120 (2002) 1644-1650
30. Ng E.W., and Adamis A.P. Targeting angiogenesis, the underlying disorder in neovascular age-related macular degeneration. Can J Ophthalmol 40 (2005) 352-368
31. Ng E.W., Shima D.T., Calias P., Cunningham Jr. E.T., Guyer D.R., and Adamis A.P. Pegaptanib, a targeted anti-VEGF aptamer for ocular vascular disease. Nat Rev Drug Discov 5 (2006) 123-132
32. Gragoudas E.S., Adamis A.P., Cunningham Jr. E.T., Feinsod M., and Guyer D.R. Pegaptanib for neovascular age-related macular degeneration. N Engl J Med 351 (2004) 2805-2816
33. Cunningham Jr. E.T., Adamis A.P., Altaweel M., et al. A phase II randomized double-masked trial of pegaptanib, an anti-vascular endothelial growth factor aptamer, for diabetic macular edema. Ophthalmology 112 (2005) 1747-1757
34. Adamis A.P., Altaweel M., Bressler N.M., et al., Macugen Diabetic Retinopathy Study Group. Changes in retinal neovascularization after pegaptanib (Macugen) therapy in diabetic individuals. Ophthalmology 113 (2006) 23-28
35. Wroblewski J.J., Wells J.A., Adamis A.P., et al. Pegaptanib sodium for macular edema secondary to central retinal vein occlusion. Arch Ophthalmol 127 (2009) 374-380
36. Mechtcheriakova D., Wlachos A., Holzmüller H., Binder B.R., and Hofer E. Vascular endothelial cell growth factor-induced tissue factor expression in endothelial cells is mediated by EGR-1. Blood 93 (1999) 3811-3823
37. Sassa Y., Hata Y., Murata T., et al. Functional role of Egr-1 mediating VEGF-induced tissue factor expression in the retinal capillary endothelium. Graefes Arch Clin Exp Ophthalmol 240 (2002) 1003-1010
38. Prager F., Michels S., Kriechbaum K., et al. Intravitreal bevacizumab (Avastin) for macular oedema secondary to retinal vein occlusion: 12-month results of a prospective clinical trial. Br J Ophthalmol 92 (2008) 518-522
39. Kreutzer T.C., Alge C.S., Wolf A.H., et al. Intravitreal bevacizumab for the treatment of macular oedema secondary to branch retinal vein occlusion. Br J Ophthalmol 92 (2008) 351-355
40. Jaissle G.B., Leitritz M., Gelisken F., Ziemssen F., Bartz-Schmidt K.U., and Szurman P. One-year results after intravitreal bevacizumab for macular edema secondary to branch retinal vein occlusion. Graefes Arch Clin Exp Ophthamol 247 (2009) 27-33
41. Campochiaro P.A., Hafiz G., Shah S.M., et al. Ranibizumab for macular edema due to retinal vein occlusions; implication of VEGF as a critical stimulator. Mol Ther 16 (2008) 791-799
42. Rabena M.D., Pieramici D.J., Castellarin A.A., Nasir M.A., and Avery R.L. Intravitreal bevacizumab (Avastin) in the treatment of macular edema secondary to branch retinal vein occlusion. Retina 27 (2007) 419-425
43. Wu L., Arevalo J.F., Roca J.A., et al. Comparison of two doses of intravitreal bevacizumab (Avastin) for the treatment of macular edema secondary to branch retinal vein occlusion: results from the Pan-American Collaborative Retina Study Group at 6 months of follow-up. Retina 28 (2008) 212-219
44. Gregori N.Z., Rattan G.H., Rosenfeld P.J., et al. Safety and efficacy of intravitreal bevacizumab (Avastin) for the management of branch and hemiretinal vein occlusion. Retina 29 (2009) 913-925
45. Brown D.M., Kaiser P.K., Michels M., et al. Ranibizumab versus verteporfin for neovascular age-related macular degeneration. N Engl J Med 355 (2006) 1432-1444
46. Rosenfeld P.J., Brown D.M., Heier J.S., et al., MARINA Study Group. Ranibizumab for neovascular age-related macular degeneration. N Engl J Med 355 (2006) 1419-1431
47. Ferrara N., Damico L., Shams N., Lowman H., and Kim R. Development of ranibizumab, an anti-vascular endothelial growth factor antigen binding fragment, as therapy for neovascular age-related macular degeneration. Retina 26 (2006) 859-870
48. Ishida S., Usui T., Yamashiro K., Kaji Y., et al. VEGF164 is proinflammatory in the diabetic retina. Invest Ophthalmol Vis Sci 44 (2003) 2155-2162
49. Ishida S., Usui T., Yamashiro K., et al. VEGF164-mediated inflammation is required for pathological, but not physiological, ischemia-induced retinal neovascularization. J Exp Med 198 (2003) 483-489
50. Kamba T., Tam B.Y., Hashizume H., et al. VEGF-dependent plasticity of fenestrated capillaries in the normal adult microvasculature. Am J Physiol Heart Circ Physiol 290 (2006) H560-H576
51. Blaauwgeers H.G., Holtkamp G.M., Rutten H., et al. Polarized vascular endothelial growth factor secretion by human retinal pigment epithelium and localization of vascular endothelial growth factor receptors on the inner choriocapillaris. Evidence for a trophic paracrine relation. Am J Pathol 155 (1999) 421-428
52. Nishijima K., Ng Y.S., Zhong L., et al. Vascular endothelial growth factor-A is a survival factor for retinal neurons and a critical neuroprotectant during the adaptive response to ischemic injury. Am J Pathol 171 (2007) 53-67
53. Klein R., Klein B.E., Moss S.E., and Meuer S.M. The epidemiology of retinal vein occlusion: the Beaver Dam Eye Study. Trans Am Ophthalmol Soc 98 (2000) 133-141
54. Hayreh S.S., Zimmerman B., McCarthy M.J., and Podhajsky P. Systemic diseases associated with various types of retinal vein occlusion. Am J Ophthalmol 131 (2001) 61-77
55. Ueta T., Yanagi Y., Tamaki Y., and Yamaguchi T. Cerebrovascular accidents in ranibizumab. Ophthalmology 116 (2009) 362
56. Singerman L.J., Masonson H., Patel M., et al. Pegaptanib sodium for neovascular age-related macular degeneration: third-year safety results of the V.I.S.I.O.N. trial. Br J Ophthalmol 92 (2008) 1606-1611
57. Esrick E., Subramanian M.L., Heier J.S., et al. Multiple laser treatments for macular edema attributable to branch retinal vein occlusion. Am J Ophthalmol 139 (2005) 653-657